These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29699840)

  • 21. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice.
    Chai X; Li D; Cao X; Zhang Y; Mu J; Lu W; Xiao X; Li C; Meng J; Chen J; Li Q; Wang J; Meng A; Zhao M
    Sci Rep; 2015 May; 5():10181. PubMed ID: 25970748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
    Quarta A; Melpignano A; Quarta G
    Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
    Steensma DP; Gattermann N
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights into transfusion-related iron toxicity: Implications for the oncologist.
    Porter JB; de Witte T; Cappellini MD; Gattermann N
    Crit Rev Oncol Hematol; 2016 Mar; 99():261-71. PubMed ID: 26806144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y; Long Z; Chen M; Han B; Hou B; Feng F
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
    Tesch H; Ihling C
    Onkologie; 2013; 36(4):205-8. PubMed ID: 23548970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron overload and chelation therapy in myelodysplastic syndromes.
    Temraz S; Santini V; Musallam K; Taher A
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
    Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
    Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematopoietic recovery after administration of deferasirox for transfusional iron overload in a case of myelodysplastic syndrome.
    OKABE H; SUZUKI T; OMORI T; MORI M; UEHARA E; HATANO K; UEDA M; MATSUYAMA T; TOSHIMA M; QZAKI K; NAGAI T; MUROI K; OZAWA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1626-9. PubMed ID: 20009438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron chelation therapy in low risk myelodysplastic syndrome.
    Killick SB
    Br J Haematol; 2017 May; 177(3):375-387. PubMed ID: 28300275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?
    Bird RJ; Kenealy M; Forsyth C; Wellwood J; Leahy MF; Seymour JF; To LB
    Intern Med J; 2012 Apr; 42(4):450-5. PubMed ID: 22498118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow.
    Park M; Park CJ; Cho YW; Jang S; Lee JH; Lee JH; Lee KH; Lee YH
    Exp Hematol; 2017 Jan; 45():56-63. PubMed ID: 27693387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.